$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914056402 Filed on August 04, 2014

Income Statement

Concept	2014 Q2	2013 Q4	2013 Q2
Revenue	$4.038B	$3.885B	$2.422B
YoY Change	66.72%	66.67%	6.93%
Cost Of Revenue	$649.0M	$626.0M	$387.0M
YoY Change	67.7%	61.34%	-0.51%
Gross Profit	$3.389B	$3.259B	$2.035B
YoY Change	66.54%	67.73%	8.48%
Gross Profit Margin	83.93%	83.89%	84.02%
Selling, General & Admin	$1.956B	$1.872B	$1.208B
YoY Change	61.92%	71.59%	14.61%
% of Gross Profit	57.72%	57.44%	59.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$209.0M	$191.0M	$121.0M
YoY Change	72.73%	64.66%	16.35%
% of Gross Profit	6.17%	5.86%	5.95%
Operating Expenses	$3.142B	$3.006B	$1.820B
YoY Change	72.64%	74.46%	7.57%
Operating Profit	$207.0M	$253.0M	$202.0M
YoY Change	2.48%	15.0%	12.22%
Interest Expense	$190.0M	-$182.0M	$98.00M
YoY Change	93.88%	65.45%	-3.92%
% of Operating Profit	91.79%	-71.94%	48.51%
Other Income/Expense, Net
YoY Change
Pretax Income	$17.00M	-$15.00M	-$66.00M
YoY Change	-125.76%	-115.46%	-184.62%
Income Tax	$8.000M	-$8.000M	-$20.00M
% Of Pretax Income	47.06%
Net Earnings	-$7.000M	-$24.00M	-$43.00M
YoY Change	-83.72%	-148.98%	115.0%
Net Earnings / Revenue	-0.17%	-0.62%	-1.78%
Basic Earnings Per Share	-$0.27		-$0.49
Diluted Earnings Per Share	-$0.27	-$243.4K	-$0.49
COMMON SHARES
Basic Shares Outstanding	97.68M shares	99.23M shares	103.0M shares
Diluted Shares Outstanding	97.68M shares		103.0M shares

Balance Sheet

Concept	2014 Q2	2013 Q4	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$406.0M	$113.0M	$90.00M
YoY Change	351.11%	-68.96%	9.76%
Cash & Equivalents	$406.0M	$113.0M	$90.00M
Short-Term Investments
Other Short-Term Assets	$700.0M	$789.0M	$600.0M
YoY Change	16.67%	72.27%	-37.43%
Inventory	$264.0M	$262.0M	$153.0M
Prepaid Expenses
Receivables	$2.171B	$1.965B	$1.369B
Other Receivables	$34.00M	$0.00	$12.00M
Total Short-Term Assets	$4.208B	$3.710B	$2.574B
YoY Change	63.48%	38.38%	0.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.771B	$7.691B	$4.326B
YoY Change	79.63%	79.15%	3.47%
Goodwill	$3.200B	$3.042B	$970.0M
YoY Change	229.9%	232.1%
Intangibles
YoY Change
Long-Term Investments	$362.0M	$56.00M	$166.0M
YoY Change	118.07%	154.55%	38.33%
Other Assets	$328.0M	$347.0M	$504.0M
YoY Change	-34.92%	1.46%	46.09%
Total Long-Term Assets	$12.70B	$12.42B	$6.582B
YoY Change	92.94%	95.19%	11.16%
TOTAL ASSETS
Total Short-Term Assets	$4.208B	$3.710B	$2.574B
Total Long-Term Assets	$12.70B	$12.42B	$6.582B
Total Assets	$16.91B	$16.13B	$9.156B
YoY Change	84.65%	78.35%	7.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.015B	$1.075B	$587.0M
YoY Change	72.91%	48.89%	-8.85%
Accrued Expenses	$876.0M	$820.0M	$493.0M
YoY Change	77.69%	51.85%	0.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$622.0M	$153.0M	$71.00M
YoY Change	776.06%	62.77%	-70.04%
Total Short-Term Liabilities	$3.384B	$2.928B	$1.658B
YoY Change	104.1%	66.08%	-11.43%
LONG-TERM LIABILITIES
Long-Term Debt	$10.94B	$10.70B	$5.564B
YoY Change	96.66%	107.37%	23.34%
Other Long-Term Liabilities	$484.0M	$446.0M	$608.0M
YoY Change	-20.39%	46.23%	-29.05%
Total Long-Term Liabilities	$484.0M	$446.0M	$608.0M
YoY Change	-20.39%	46.23%	-88.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.384B	$2.928B	$1.658B
Total Long-Term Liabilities	$484.0M	$446.0M	$608.0M
Total Liabilities	$15.76B	$15.01B	$8.095B
YoY Change	94.65%	92.13%	11.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.480B	-$1.422B	-$1.426B
YoY Change	3.79%	10.4%
Common Stock	$7.000M	$7.000M	$7.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.378B	$2.378B	$2.170B
YoY Change	9.59%	20.16%
Treasury Stock Shares	47.20M shares	47.20M shares	42.17M shares
Shareholders Equity	$723.0M	$755.0M	$895.0M
YoY Change
Total Liabilities & Shareholders Equity	$16.91B	$16.13B	$9.156B
YoY Change	84.65%	78.35%	7.91%

Cashflow Statement

Concept	2014 Q2	2013 Q4	2013 Q2
OPERATING ACTIVITIES
Net Income	-$7.000M	-$24.00M	-$43.00M
YoY Change	-83.72%	-148.98%	115.0%
Depreciation, Depletion And Amortization	$209.0M	$191.0M	$121.0M
YoY Change	72.73%	64.66%	16.35%
Cash From Operating Activities	$266.0M	$255.0M	$160.0M
YoY Change	66.25%	-0.39%	-34.16%
INVESTING ACTIVITIES
Capital Expenditures	-$242.0M	-$293.0M	-$123.0M
YoY Change	96.75%	97.97%	6.96%
Acquisitions
YoY Change
Other Investing Activities	-$43.00M	-$1.362B	-$33.00M
YoY Change	30.3%	710.71%	-1200.0%
Cash From Investing Activities	-$285.0M	-$1.655B	-$156.0M
YoY Change	82.69%	423.73%	39.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	284.0M	1.431B	-9.000M
YoY Change	-3255.56%	319.65%	-94.12%
NET CHANGE
Cash From Operating Activities	266.0M	255.0M	160.0M
Cash From Investing Activities	-285.0M	-1.655B	-156.0M
Cash From Financing Activities	284.0M	1.431B	-9.000M
Net Change In Cash	265.0M	31.00M	-5.000M
YoY Change	-5400.0%	-88.97%	-77.27%
FREE CASH FLOW
Cash From Operating Activities	$266.0M	$255.0M	$160.0M
Capital Expenditures	-$242.0M	-$293.0M	-$123.0M
Free Cash Flow	$508.0M	$548.0M	$283.0M
YoY Change	79.51%	35.64%	-20.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.01
CY2014Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	11564000000	USD
CY2013Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	10839000000	USD
CY2014Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	622000000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	149000000	USD
CY2014Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10942000000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10690000000	USD
	thc	Debt Instrument Covenant Secured Debt To Ebitda Ratio DebtInstrumentCovenantSecuredDebtToEBITDARatio	3.00	pure
	thc	Debt Instrument Issuance Fee DebtInstrumentIssuanceFee	0.00125	pure
CY2014Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.01875	pure
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2014Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	428000000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1015000000	USD
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	407000000	USD
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	28000000	USD
	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	79	item
	thc	Number Of Provider Based Out Patient Centers Operated By Subsidiaries NumberOfProviderBasedOutPatientCentersOperatedBySubsidiaries	189	item
	thc	Number Of Health Plans Operated By Subsidiaries NumberOfHealthPlansOperatedBySubsidiaries	6	item
CY2014Q2	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	4362000000	USD
CY2013Q2	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	2629000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	thc	Business Combination Acquisition Related Transaction Costs BusinessCombinationAcquisitionRelatedTransactionCosts	4000000	USD
	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	8668000000	USD
	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	5223000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1859000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1715000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	618000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	523000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1241000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1192000000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	406000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2014Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	144000000	USD
CY2013Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	245000000	USD
CY2014Q2	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	79000000	USD
CY2013Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	62000000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	114000000	USD
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	193000000	USD
CY2014Q2	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	64000000	USD
CY2013Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	138000000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	60000000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	79000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	128000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	241000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	188000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	128000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	124000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	342000000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2171000000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1965000000	USD
	thc	Allowance For Doubtful Accounts As Percent Of Accounts Receivable AllowanceForDoubtfulAccountsAsPercentOfAccountsReceivable	0.255	pure
CY2013	thc	Allowance For Doubtful Accounts As Percent Of Accounts Receivable AllowanceForDoubtfulAccountsAsPercentOfAccountsReceivable	0.232	pure
CY2014Q2	us-gaap	Inventory Net InventoryNet	264000000	USD
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1000000	USD
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3000000	USD
CY2014Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	19000000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97419000	shares
	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-37000000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97419000	shares
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.38
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-33000000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	3000000	USD
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	25000000	USD
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	53000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	7000000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	5000000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	9000000	USD
	us-gaap	Business Exit Costs1 BusinessExitCosts1	1000000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	10000000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	26000000	USD
CY2014Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2350603	shares
CY2014Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1932972	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y9M18D
CY2014Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	25.78
CY2014Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	24.03
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1218000000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	873000000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	981000000	USD
	us-gaap	Profit Loss ProfitLoss	-23000000	USD
	us-gaap	Profit Loss ProfitLoss	-126000000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	18000000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4000000	USD
	thc	Adjustments To Additional Paid In Capital Sale Of Joint Venture Interest AdjustmentsToAdditionalPaidInCapitalSaleOfJointVentureInterest	53000000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	29000000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	13000000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	192000000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22000000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29000000	USD
	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	127000000	USD
	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	52000000	USD
CY2014Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	64000000	USD
CY2013Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	46000000	USD
CY2012Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	USD
CY2013Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	9000000	USD
	thc	Gain Loss Total Related To Litigation Settlement GainLossTotalRelatedToLitigationSettlement	33000000	USD
	thc	Gain Loss Total Related To Litigation Settlement GainLossTotalRelatedToLitigationSettlement	2000000	USD
	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	12000000	USD
	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	3000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10000000	USD
	thc	Income Tax Expense Benefit Change In Valuation Allowance Of Deferred Tax Assets IncomeTaxExpenseBenefitChangeInValuationAllowanceOfDeferredTaxAssets	3000000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	43000000	USD
CY2014Q2	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	1000000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97677000	shares
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
CY2014Q2	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2014Q2	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10000000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97677000	shares
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.11
CY2013Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-53000000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103010000	shares
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.52
CY2013Q2	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2013Q2	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-53000000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103010000	shares
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.52
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-37000000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.38
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-139000000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103557000	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.34
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-139000000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103557000	shares
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.34
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2123000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2053000	shares
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2326000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2282000	shares
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1000000	USD
CY2013Q4	us-gaap	Alternative Investments Fair Value Disclosure AlternativeInvestmentsFairValueDisclosure	2000000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	62000000	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	65000000	USD
CY2014Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2000000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-16000000	USD
CY2014Q2	us-gaap	Alternative Investments Fair Value Disclosure AlternativeInvestmentsFairValueDisclosure	2000000	USD
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	66000000	USD
CY2014Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	70000000	USD
CY2014Q2	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.076	pure
CY2013Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.035	pure
	thc	Business Combination Acquisition Transaction Related Costs BusinessCombinationAcquisitionTransactionRelatedCosts	4000000	USD
	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	79	item
	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	20553	item
CY2014Q2	us-gaap	Assets Assets	16907000000	USD
CY2013Q4	us-gaap	Assets Assets	16130000000	USD
CY2014Q2	thc	Capital Expenditure CapitalExpenditure	242000000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	209000000	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	121000000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	190000000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	98000000	USD
	us-gaap	Interest Expense InterestExpense	372000000	USD
	us-gaap	Interest Expense InterestExpense	201000000	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013Q2	thc	Capital Expenditure CapitalExpenditure	123000000	USD
	thc	Capital Expenditure CapitalExpenditure	523000000	USD
	thc	Capital Expenditure CapitalExpenditure	256000000	USD
CY2014Q2	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	4042000000	USD
CY2013Q2	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2422000000	USD
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7968000000	USD
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	4809000000	USD
CY2014Q2	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	460000000	USD
CY2013Q2	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	336000000	USD
	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	847000000	USD
	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	610000000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	402000000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	235000000	USD
CY2014Q2	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	32000000	USD
CY2013Q2	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	11000000	USD
	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	53000000	USD
	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	25000000	USD
CY2014Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12000000	USD
CY2013Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-2000000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-15000000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-2000000	USD
CY2013Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-171000000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-348000000	USD
CY2014Q2	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	17000000	USD
CY2013Q2	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	-66000000	USD
	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	5000000	USD
	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	-200000000	USD
CY2014Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2013Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	207000000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	202000000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	17000000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	700000000	USD
	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Operating Revenues</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt;" size="2">Compact with Uninsured Patients</font></i> <font style="FONT-SIZE: 10pt;" size="2">(“Compact”) and other uninsured discount and charity programs</font><font style="FONT-SIZE: 10pt;" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts:</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 24.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="24%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three Months Ended<br />  June 30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 24.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="24%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six Months Ended<br />  June 30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2014</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">General Hospitals:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicare</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">865</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">502</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,722</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,042</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicaid</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">380</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">236</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">672</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">424</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Managed care</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,228</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,387</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,418</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,748</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Indemnity, self-pay and other</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">368</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">261</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">815</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">521</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Acute care hospitals — other revenue</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">18</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">37</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">39</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Other:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other operations</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">503</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">232</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,004</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">449</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 45%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="45%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net operating revenues before provision for doubtful accounts</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">4,362</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2,629</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">8,668</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="9%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">5,223</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr></table> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	247000000	USD
	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97915606	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q4	us-gaap	Inventory Net InventoryNet	262000000	USD
CY2014Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	34000000	USD
CY2013Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	633000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	581000000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	789000000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	4208000000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3710000000	USD
CY2014Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	362000000	USD
CY2013Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	405000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	125000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	90000000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7771000000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7691000000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	3200000000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	3042000000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1075000000	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	669000000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	631000000	USD
CY2014Q2	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	162000000	USD
CY2013Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	156000000	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	207000000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	198000000	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	709000000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	719000000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3384000000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2928000000	USD
CY2014Q2	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	567000000	USD
CY2013Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	543000000	USD
CY2014Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	380000000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4594000000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4178000000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	398000000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	484000000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	446000000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	15757000000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	15005000000	USD
CY2014Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	277000000	USD
CY2013Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	247000000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4572000000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24000000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1480000000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1422000000	USD
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2378000000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2378000000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	723000000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	755000000	USD
CY2014Q2	us-gaap	Minority Interest MinorityInterest	150000000	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	123000000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16907000000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16130000000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	753000000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	589000000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3898000000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145010828	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144057351	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	47196972	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	47197722	shares
CY2014Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	320000000	USD
CY2013Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	207000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	700000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	414000000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	4809000000	USD
CY2014Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1956000000	USD
CY2013Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1166000000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3877000000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2327000000	USD
CY2014Q2	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	649000000	USD
CY2013Q2	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	387000000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1277000000	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	771000000	USD
CY2014Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1035000000	USD
CY2013Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	567000000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2034000000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1135000000	USD
CY2014Q2	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-58000000	USD
CY2013Q2	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-34000000	USD
	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-67000000	USD
	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-34000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	377000000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	348000000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-66000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-200000000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-20000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-73000000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	9000000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-46000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-127000000	USD
CY2014Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-7000000	USD
CY2013Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	6000000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-15000000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	3000000	USD
CY2014Q2	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	18000000	USD
CY2013Q2	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	18000000	USD
	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2014Q2	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-9000000	USD
CY2013Q2	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	3000000	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-12000000	USD
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	2000000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-16000000	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-21000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1000000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	-7000000	USD
CY2013Q2	us-gaap	Profit Loss ProfitLoss	-43000000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19000000	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	35000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	12000000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26000000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-138000000	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-21000000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1000000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	-2000000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	0	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.16
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.22
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-65000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	47000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	5000000	USD
	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	84000000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.16
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.03
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.22
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.01
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	-3000000	USD
	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3000000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	5000000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	6000000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	2000000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	2000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4000000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-43000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-19000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-126000000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	19000000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	7000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	35000000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12000000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23000000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-138000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-76000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	26000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19000000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	14000000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	9000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	18000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	937000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	445000000	USD
	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	-78000000	USD
	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	166000000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	17000000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	128000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	523000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	256000000	USD
	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	19000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-12000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-7000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	42000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16000000	USD
	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	3000000	USD
	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	3000000	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	14000000	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	-6000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-576000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-260000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1300000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	620000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	895000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	653000000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	68000000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1967000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	1108000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	1907000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	192000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	19000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	30000000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	20000000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	10000000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	13000000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	98000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	622000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-142000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	293000000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-274000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	360000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	226000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-19000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-8000000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90000000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364000000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2000000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	22000000	USD
	thc	Loss Contingency Reserves Assumed In Acquisition LossContingencyReservesAssumedInAcquisition	-3000000	USD
	thc	Loss Contingency Reserves Assumed In Acquisition LossContingencyReservesAssumedInAcquisition	0	USD
CY2014Q2	thc	Gain Loss Related To Litigation Settlement From Discontinued Operations GainLossRelatedToLitigationSettlementFromDiscontinuedOperations	-18000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	18000000	USD
CY2014Q2	thc	Finite Lived Estimated Intangible Assets Net FiniteLivedEstimatedIntangibleAssetsNet	1151000000	USD

Files In Submission

Name	View Source	Status
0001104659-14-056402-index-headers.html	Edgar Link	pending
0001104659-14-056402-index.html	Edgar Link	pending
0001104659-14-056402.txt	Edgar Link	pending
0001104659-14-056402-xbrl.zip	Edgar Link	pending
a14-13869_110q.htm	Edgar Link	pending
a14-13869_1ex31da.htm	Edgar Link	pending
a14-13869_1ex31db.htm	Edgar Link	pending
a14-13869_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20140630.xml	Edgar Link	completed
thc-20140630.xsd	Edgar Link	pending
thc-20140630_cal.xml	Edgar Link	unprocessable
thc-20140630_def.xml	Edgar Link	unprocessable
thc-20140630_lab.xml	Edgar Link	unprocessable
thc-20140630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2014 Q2 Form 10-Q Financial Statement

#000110465914056402 Filed on August 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2014 Q2 Form 10-Q Financial Statement

#000110465914056402 Filed on August 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc